|
ATP13A3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62547753035369E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.80619971704255E-11 |
| Normal-vs-Stage2 |
5.12160003296458E-09 |
| Normal-vs-Stage3 |
1.00053298979219E-12 |
| Normal-vs-Stage4 |
1.1518563880486E-12 |
| Stage1-vs-Stage2 |
1.250210E-01 |
| Stage1-vs-Stage3 |
2.522100E-02 |
| Stage1-vs-Stage4 |
1.835110E-04 |
| Stage2-vs-Stage3 |
9.079400E-01 |
| Stage2-vs-Stage4 |
1.370200E-01 |
| Stage3-vs-Stage4 |
1.261810E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.13464793116691E-13 |
| Normal-vs-AfricanAmerican |
3.78420000000101E-05 |
| Normal-vs-Asian |
2.61090005171383E-09 |
| Caucasian-vs-AfricanAmerican |
8.916600E-01 |
| Caucasian-vs-Asian |
4.867000E-01 |
| AfricanAmerican-vs-Asian |
7.222800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.23020046874467E-10 |
| Normal-vs-Female |
1.73183689611278E-12 |
| Male-vs-Female |
3.716400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.34209998670087E-09 |
| Normal-vs-Age(41-60Yrs) |
1.25122134875255E-13 |
| Normal-vs-Age(61-80Yrs) |
3.2428948415486E-11 |
| Normal-vs-Age(81-100Yrs) |
2.878700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.203600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.521700E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.156800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.670600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.039000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.772400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.807900E-02 |
| Classical-VS-Follicular |
4.234400E-01 |
| Classical-VS-Other |
5.657400E-01 |
| Classical-VS-Normal |
1.57489999930149E-08 |
| Tall-VS-Follicular |
1.626830E-01 |
| Tall-VS-Other |
1.125170E-01 |
| Tall-VS-Normal |
7.31799953967993E-10 |
| Follicular-VS-Other |
4.378000E-01 |
| Follicular-VS-Normal |
1.35540001444667E-09 |
| Other-VS-Normal |
5.706400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.44835271448574E-13 |
| Normal-vs-N1 |
7.96119947743534E-10 |
| N0-vs-N1 |
2.807400E-01 |
|
|
